Industry Research Showcase
Nov
2026
Description
This session features industry-sponsored preclinical and translational research spanning novel therapeutics for Alagille syndrome, PSC, alcohol use disorder, and decompensated cirrhosis, plus hepatocyte engineering advances.
Presentations
8:00 AM
- 8:15 AM
Convention Center - Bluebird Ballroom 1B
ART4, a Translation-Enhancing Antisense Oligonucleotide, Restores JAG1 Expression and Improves Liver Disease in Preclinical Models of Alagille Syndrome
Xuehai Liang, Ph.D | Abstract Presenter
8:15 AM
- 8:30 AM
Convention Center - Bluebird Ballroom 1B
Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model
John J Suschak, PhD | Abstract Presenter
8:30 AM
- 8:45 AM
Convention Center - Bluebird Ballroom 1B
Suitability of intravenous administration of Regenerative Macrophage Therapy for the treatment of decompensated cirrhosis
Lara Campana | Abstract Presenter
8:45 AM
- 9:00 AM
Convention Center - Bluebird Ballroom 1B
Targeting bile composition in PSC: RTY-406, a dual-acting ABCB4/BSEP Positive Functional Modulator reduces disease-relevant markers in a mouse model and non-human primate
Eric Bell, PhD | Abstract Presenter
9:00 AM
- 9:15 AM
Convention Center - Bluebird Ballroom 1B
Circulating protein biomarkers associated with reductions in liver fat and visceral and subcutaneous adiposity in adults with obesity and MASLD with retatrutide treatment
YoSon Park, PhD | Abstract Presenter
9:15 AM
- 9:30 AM
Convention Center - Bluebird Ballroom 1B
Closing the maturation gap: machine learning-driven optimization of hPSC-derived hepatocyte function
Christian Elabd, PhD | Abstract Presenter
